{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,12]],"date-time":"2025-10-12T04:01:56Z","timestamp":1760241716680,"version":"build-2065373602"},"reference-count":81,"publisher":"Elsevier BV","issue":"2","license":[{"start":{"date-parts":[[2020,6,1]],"date-time":"2020-06-01T00:00:00Z","timestamp":1590969600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2020,6,1]],"date-time":"2020-06-01T00:00:00Z","timestamp":1590969600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","theclinics.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Infectious Disease Clinics of North America"],"published-print":{"date-parts":[[2020,6]]},"DOI":"10.1016\/j.idc.2020.02.001","type":"journal-article","created":{"date-parts":[[2020,5,20]],"date-time":"2020-05-20T02:00:14Z","timestamp":1589940014000},"page":"179-189","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":9,"title":["Risk of Serious Infection Associated with Agents that Target T-Cell Activation and Interleukin-17 and Interleukin-23 Cytokines"],"prefix":"10.1016","volume":"34","author":[{"given":"Stanford","family":"Shoor","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.idc.2020.02.001_bib1","first-page":"110","article-title":"Mechanisms behind efficacy of tumor necrosis factors inhibitors in inflammatory bowel disease","volume":"159","author":"Olesen","year":"2016","journal-title":"Pharmacol Ther"},{"key":"10.1016\/j.idc.2020.02.001_bib2","first-page":"2287","article-title":"Frequency of infection in patients with rheumatoid arthritis compared with controls: a population-based study","volume":"46","author":"Doran","year":"2002","journal-title":"Arthritis Rheum"},{"issue":"11","key":"10.1016\/j.idc.2020.02.001_bib3","first-page":"994","article-title":"Mortality risk associated with rheumatoid arthritis in a prospective cohort of older women: results from the Iowa Women\u2019s Health Study","volume":"61","author":"Mikuls","year":"2002","journal-title":"Ann Rheum Dis"},{"issue":"1","key":"10.1016\/j.idc.2020.02.001_bib4","first-page":"56","article-title":"Comparative risk of hospitalized infection associated with biologic agents in rheumatoid arthritis patients enrolled in medicare","volume":"68","author":"Yun","year":"2016","journal-title":"Arthritis Rheumatol"},{"issue":"6","key":"10.1016\/j.idc.2020.02.001_bib5","first-page":"e0179179","article-title":"Comparative risk of hospitalized infection between biological agents in rheumatoid arthritis patients: a multicenter retrospective cohort study in Japan","volume":"12","author":"Mori","year":"2018","journal-title":"PLoS One"},{"key":"10.1016\/j.idc.2020.02.001_bib6","first-page":"825","article-title":"Risk of biologics and glucocorticoids in patients with rheumatoid arthritis undergoing arthroplasty. a cohort Study","volume":"170","author":"George","year":"2019","journal-title":"Ann Intern Med"},{"key":"10.1016\/j.idc.2020.02.001_bib7","first-page":"628","article-title":"Treatment for rheumatoid arthritis and the risk of hospitalization for pneumonia: associations with prednisone, disease-modifying antirheumatic drugs, and anti-tumor necrosis factor therapy","volume":"54","author":"Wolfe","year":"2006","journal-title":"Arthritis Rheum"},{"key":"10.1016\/j.idc.2020.02.001_bib8","first-page":"380","article-title":"Association of methotrexate and tumor necrosis factor antagonists with risk of infectious outcomes including opportunistic infections in the CORRONA registry","volume":"69","author":"Greenberg","year":"2010","journal-title":"Ann Rheum Dis"},{"issue":"7","key":"10.1016\/j.idc.2020.02.001_bib9","first-page":"990","article-title":"Risk of hospitalized bacterial infections associated with biologic treatment among US Veterans with rheumatoid arthritis","volume":"66","author":"Curtis","year":"2014","journal-title":"Arthritis Care Res"},{"issue":"8","key":"10.1016\/j.idc.2020.02.001_bib10","first-page":"1074","article-title":"Use of nonbiologic disease-modifying antirheumatic drugs and risk of infection in patients with rheumatoid arthritis","volume":"59","author":"Lacaille","year":"2008","journal-title":"Arthritis Rheum"},{"key":"10.1016\/j.idc.2020.02.001_bib11","first-page":"954","article-title":"Risk of infectious complications in patients taking glucocorticosteroids","volume":"11","author":"Stuck","year":"1989","journal-title":"Rev Infect Dis"},{"key":"10.1016\/j.idc.2020.02.001_bib12","first-page":"1843","article-title":"Real-word comparative risk of herpes virus infections in tofacitinib and biologic treated patients with rheumatoid arthritis","volume":"75","author":"Curtis","year":"2016","journal-title":"Ann Rheum Dis"},{"issue":"20","key":"10.1016\/j.idc.2020.02.001_bib13","first-page":"1907","article-title":"Treatment of rheumatoid arthritis by selective inhibition of T-cell activation with fusion protein CTLA4Ig","volume":"349","author":"Kremer","year":"2003","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.idc.2020.02.001_bib14","first-page":"222","article-title":"Registries in rheumatoid arthritis and autoimmune diseases: data from the French registries","volume":"50","author":"Mariette","year":"2011","journal-title":"Rheumatology"},{"issue":"3","key":"10.1016\/j.idc.2020.02.001_bib15","first-page":"92","article-title":"Biological response modifiers in rheumatoid arthritis: systematic review and meta-analysis of Safety","volume":"8","author":"Tank","year":"2017","journal-title":"J\u00a0Pharmacol Pharmacother"},{"key":"10.1016\/j.idc.2020.02.001_bib16","first-page":"1","article-title":"Infections requiring hospitalization in the abatacept clinical development program: an epidemiological assessment","volume":"12","author":"Simon","year":"2010","journal-title":"Arthritis Res Ther"},{"key":"10.1016\/j.idc.2020.02.001_bib17","first-page":"25","article-title":"Risk of serious infections during rituximab, abatacept and anakinra treatments for rheumatoid arthritis: meta-analysis of randomised placebo-controlled trials","volume":"68","author":"Salliot","year":"2009","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.idc.2020.02.001_bib18","first-page":"456","article-title":"Risk of serious infections in tocilizumab versus other biologic drugs in patients with rheumatoid arthritis: a multi-database cohort study","volume":"78","author":"Pawar","year":"2019","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.idc.2020.02.001_bib19","first-page":"1708","article-title":"The 6-month safety and efficacy of abatacept in patients with rheumatoid arthritis who underwent a washout after anti-tumour necrosis factor therapy or were directly switched to abatacept: the ARRIVE trial","volume":"68","author":"Schiff","year":"2009","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.idc.2020.02.001_bib20","first-page":"320","article-title":"Risk of serious infections in patients with rheumatoid arthritis treated in routine care with abatacept, rituximab and tocilizumab in Denmark and Sweden","volume":"78","author":"Lederballe Gr\u00f8n","year":"2019","journal-title":"Ann Rheum Dis"},{"issue":"9990","key":"10.1016\/j.idc.2020.02.001_bib21","first-page":"258","article-title":"Risk of serious infection in biological treatment of patients with rheumatoid arthritis: a systematic review and meta-analysis","volume":"386","author":"Singh","year":"2015","journal-title":"Lancet"},{"issue":"12","key":"10.1016\/j.idc.2020.02.001_bib22","first-page":"2628","article-title":"Tofacitinib versus biologic treatment in patient with active rheumatoid arthritis who have had an inadequate response to tumor necrosis factor inhibitors: results from a network meta-analysis","volume":"38","author":"Vieira","year":"2016","journal-title":"Clin Ther"},{"issue":"2","key":"10.1016\/j.idc.2020.02.001_bib23","article-title":"Adverse effects of biologics: a network meta-analysis and Cochrane overview","author":"Singh","year":"2011","journal-title":"Cochrane Database Syst Rev"},{"key":"10.1016\/j.idc.2020.02.001_bib24","unstructured":"Singh JA, Wells GA, Christensen R, et al. Adverse effects of biologics: a network meta-analysis and Cochrane overview. Cochrane Database of Systematic Reviews 2011, Issue 2. The Cochrane Collaboration. London: John Wiley & Sons Ltd; 2011. p.1-57."},{"issue":"6","key":"10.1016\/j.idc.2020.02.001_bib25","first-page":"1053","article-title":"Abatacept initiation in rheumatoid arthritis and the risk of serious infection: a population-based study","volume":"48","author":"Montastruc","year":"2019","journal-title":"Semin Arthritis Rheum"},{"key":"10.1016\/j.idc.2020.02.001_bib26","first-page":"1872","article-title":"Risk of tuberculosis in patients with chronic immune-mediated inflammatory diseases treated with biologics and tofacitinib: a systematic review and meta-analysis of randomized controlled trials and long-term extension studies","volume":"53","author":"Souto","year":"2014","journal-title":"Rheumatology"},{"issue":"5","key":"10.1016\/j.idc.2020.02.001_bib27","first-page":"769","article-title":"A\u00a0case of disseminated histoplasmosis in a patient with rheumatoid arthritis on abatacept","volume":"33","author":"Jain","year":"2018","journal-title":"J\u00a0Gen Intern Med"},{"issue":"3","key":"10.1016\/j.idc.2020.02.001_bib28","first-page":"437","article-title":"Abatacept treatment for rheumatoid arthritis","volume":"50","author":"Schiff","year":"2011","journal-title":"Rheumatology"},{"issue":"2","key":"10.1016\/j.idc.2020.02.001_bib29","first-page":"1","article-title":"Long-term treatment with abatacept or tocilizumab does not increase Epstein-Barr virus load in patients with rheumatoid arthritis - A three years retrospective study","volume":"12","author":"Nathalie- Balandraud","year":"2017","journal-title":"PLoS One"},{"issue":"6","key":"10.1016\/j.idc.2020.02.001_bib30","first-page":"738","article-title":"Safety of abatacept in rheumatoid arthritis with serologic evidence of past or present hepatitis B virus infection","volume":"68","author":"Padovan","year":"2016","journal-title":"Arthritis Care Res"},{"key":"10.1016\/j.idc.2020.02.001_bib31","first-page":"443","article-title":"Rational development of LEA29Y (belatacept), a high-affinity variant of CTLA4-Ig with potent immunosuppressive properties","volume":"5","author":"Larsen","year":"2005","journal-title":"Am J Transplant"},{"key":"10.1016\/j.idc.2020.02.001_bib32","first-page":"355","article-title":"Introduction to the use of belatacept: a fusion protein for the prevention of posttransplant rejection","volume":"6","author":"Ippoliti","year":"2012","journal-title":"Biologics"},{"issue":"26","key":"10.1016\/j.idc.2020.02.001_bib33","first-page":"2600","article-title":"Belatacept and long-term outcomes in kidney transplantation","volume":"374","author":"Vincenti","year":"2016","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.idc.2020.02.001_bib34","first-page":"547","article-title":"A\u00a0phase III study of belatacept versus cyclosporine in kidney transplant from extended criteria donors (BENEFIT-EXT Study)","volume":"10","author":"Durrbach","year":"2010","journal-title":"Am J Transplant"},{"issue":"1164","key":"10.1016\/j.idc.2020.02.001_bib35","first-page":"1","article-title":"Efficacy and safety of belatacept treatment in renal allograft recipients at high cardiovascular risk \u2013 a single center experience","volume":"8","author":"Neuwirt","year":"2019","journal-title":"J\u00a0Clin Med"},{"issue":"5","key":"10.1016\/j.idc.2020.02.001_bib36","first-page":"587","article-title":"Safety and efficacy outcomes 3 years after switching to belatacept from a calcineurin inhibitor in kidney transplant recipients: results from a phase 2 randomized trial","volume":"69","author":"Griny\u00f3","year":"2017","journal-title":"Am J Kidney Dis"},{"issue":"12","key":"10.1016\/j.idc.2020.02.001_bib37","first-page":"1528","article-title":"Belatacept-based regimens versus a cyclosporine A-based regimen in kidney transplant recipients: 2-year results from the BENEFIT and BENEFIT-EXT studies","volume":"90","author":"Larsen","year":"2010","journal-title":"Transplantation"},{"key":"10.1016\/j.idc.2020.02.001_bib38","unstructured":"Launay, M, Guitard, J, Dorent, et\u00a0al. Belateacept-based immunosuppression: a calcineurin inhibitor-spraing, regimen in heart transplant patients. To be presented at the ASTS Winter Symposium. American Society of Transplant Surgeons. Miami, Florida, January 9-12, 2020."},{"issue":"1","key":"10.1016\/j.idc.2020.02.001_bib39","first-page":"171","article-title":"Maintenance belatacept-based immunosuppression in lung transplantation recipients who failed calcineurin inhibitors","volume":"102","author":"Iasella","year":"2018","journal-title":"Transplantation"},{"issue":"2","key":"10.1016\/j.idc.2020.02.001_bib40","first-page":"127","article-title":"Inhibition of interleukin-17, interleukin-23 and the TH17 cell pathway in the treatment of psoriatic arthritis and psoriasis","volume":"27","author":"Mease","year":"2015","journal-title":"Curr Opin Rheumatol"},{"issue":"52","key":"10.1016\/j.idc.2020.02.001_bib41","first-page":"52","article-title":"Effects of AIN457, a fully human antibody to interleukin-17A, on psoriasis, rheumatoid arthritis, and Uveitis","volume":"2","author":"Hueber","year":"2010","journal-title":"Sci Transl Med"},{"issue":"1","key":"10.1016\/j.idc.2020.02.001_bib42","first-page":"1","article-title":"IL-17 cytokines in immunity and inflammation","volume":"2","author":"Jin","year":"2013","journal-title":"Emerg Microbes Infect"},{"key":"10.1016\/j.idc.2020.02.001_bib43","first-page":"1","article-title":"Long-term safety of secukinumab in patients with moderate-to-severe plaque psoriasis, psoriatic arthritis, and ankylosing spondylitis: integrated pooled clinical trial and post-marketing surveillance data","volume":"21","author":"Deodhar","year":"2019","journal-title":"Arthritis Res Ther"},{"issue":"2","key":"10.1016\/j.idc.2020.02.001_bib44","first-page":"1","article-title":"Adverse drug events observed with 150mg versus 300mg secukinumab for the treatment of moderate to severe plaque psoriasis A systematic review and meta-analysis","volume":"98","author":"Zhang","year":"2019","journal-title":"Medicine"},{"key":"10.1016\/j.idc.2020.02.001_bib45","first-page":"831","article-title":"Andrew Blauvelt Guselkumab versus secukinumab for the treatment of moderate-to-severe psoriasis (ECLIPSE): results from a phase 3, randomised controlled trial","volume":"394","author":"Reich","year":"2019","journal-title":"Lancet"},{"key":"10.1016\/j.idc.2020.02.001_bib46","first-page":"890","article-title":"Secukinumab improves active psoriatic arthritis symptoms and inhibits radiographic progression: primary results from the randomised, double-blind, phase III FUTURE 5 study","volume":"77","author":"Mease","year":"2018","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.idc.2020.02.001_bib47","unstructured":"Mrowietz U, Bachelez H, Burden DA, et al. Secukinumab for moderate-to-sever palmoplantar pustular psoriasis: Result of the 2 PRECISE study. J Am Acod Dermatol 2019;80(5):1344\u201352."},{"issue":"6025","key":"10.1016\/j.idc.2020.02.001_bib48","first-page":"65","article-title":"Chronic mucocutaneous candidiasis in humans with inborn errors of interleukin-17 immunity","volume":"332","author":"Puel","year":"2011","journal-title":"Science"},{"key":"10.1016\/j.idc.2020.02.001_bib49","first-page":"829","article-title":"Safety profile of secukinumab in treatment of patients with psoriasis and concurrent hepatitis B or C: a multicentric prospective cohort study","volume":"98","author":"Chiu","year":"2018","journal-title":"Acta Derm Venereol"},{"issue":"12","key":"10.1016\/j.idc.2020.02.001_bib50","first-page":"1255","article-title":"Brodalumb for the treatment of psoriasis","volume":"12","author":"Galluzzo","year":"2016","journal-title":"Expert Rev Clin Immunol"},{"issue":"5","key":"10.1016\/j.idc.2020.02.001_bib51","first-page":"283","article-title":"Brodalumab: the first anti-IL-17 receptor agent for psoriasis","volume":"53","author":"Puig","year":"2017","journal-title":"Drugs Today (Barc)"},{"issue":"13","key":"10.1016\/j.idc.2020.02.001_bib52","first-page":"1181","article-title":"Brodalumab, an antiinterleukin-17-receptor antibody for psoriasis","volume":"366","author":"Papp","year":"2012","journal-title":"N\u00a0Engl J Med"},{"issue":"2","key":"10.1016\/j.idc.2020.02.001_bib53","first-page":"273","article-title":"A\u00a0prospective phase Ill, randomized, double-blind, placebo-controlled study of brodalumab in patients with moderate-to-severe plaque psoriasis","volume":"175","author":"Papp","year":"2016","journal-title":"Br J Dermatol"},{"issue":"14","key":"10.1016\/j.idc.2020.02.001_bib54","first-page":"1318","article-title":"Phase 3 studies comparing brodalumab with ustekinumab in psoriasis","volume":"373","author":"Lebwohl","year":"2015","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.idc.2020.02.001_bib55","first-page":"439","article-title":"Safety and efficacy of brodalumb for moderate -to- severe plaque psoriasis","volume":"37","author":"Attia","year":"2017","journal-title":"Clin Drug Investig"},{"issue":"2","key":"10.1016\/j.idc.2020.02.001_bib56","first-page":"294","article-title":"Efficacy and safety of ixekizumab over 4 years of open-label treatment in a phase 2 study in chronic plaque psoriasis","volume":"79","author":"Zachariae","year":"2018","journal-title":"J\u00a0Am Acad Dermatol"},{"issue":"10163","key":"10.1016\/j.idc.2020.02.001_bib57","first-page":"2441","volume":"392","author":"van der Heijde","year":"2018","journal-title":"Lancet"},{"issue":"3","key":"10.1016\/j.idc.2020.02.001_bib58","first-page":"367","article-title":"Safety of ixekizumab in patients with psoriatic arthritis: results from a pooled analysis of three clinical trials","volume":"71","author":"Mease","year":"2019","journal-title":"Arthritis Care Res"},{"key":"10.1016\/j.idc.2020.02.001_bib59","first-page":"325","article-title":"Long-term efficacy and safety of ixekizumab in Japanesepatients with erythrodermic or generalized pustular psoriasis: subgroup analyses of an open-label, phase 3 study (UNCOVER-J)","volume":"33","author":"Okubo","year":"2019","journal-title":"J\u00a0Eur Acad Dermatol Venereol"},{"issue":"3","key":"10.1016\/j.idc.2020.02.001_bib60","first-page":"594","article-title":"Short-term efficacy and safety of new biologic agents targeting IL -23\/Th17 pathway for moderate to severe plaque psoriasis: a systematic review and network meta -analysis","volume":"176","author":"G\u00f3mez-Garc\u00eda","year":"2017","journal-title":"Br J Dermatol"},{"issue":"5","key":"10.1016\/j.idc.2020.02.001_bib61","first-page":"731","article-title":"Long-term safety experience of ustekinumab in patients with moderate-to-severe psoriasis (Part I or II): results from analyses of general safety parameters from pooled phase 2 and 3 clinical trials","volume":"66","author":"Lebwohl","year":"2012","journal-title":"J\u00a0Am Acad Dermatol"},{"issue":"5","key":"10.1016\/j.idc.2020.02.001_bib62","first-page":"742","article-title":"Long-term safety experience of ustekinumab in patients with moderate to severe psoriasis (Part II of II): results from analyses of infections and malignancy from pooled phase II and III clinical trials","volume":"66","author":"Gordon","year":"2012","journal-title":"J\u00a0Am Acad Dermatol"},{"issue":"12","key":"10.1016\/j.idc.2020.02.001_bib63","first-page":"1535","article-title":"Long-term efficacy of ustekinumab in patients with moderate-to-severe psoriasis treated for up to 5 years in the PHOENIX 1 study","volume":"27","author":"Kimball","year":"2013","journal-title":"J\u00a0Eur Acad Dermatol Venereol"},{"issue":"5","key":"10.1016\/j.idc.2020.02.001_bib64","first-page":"1371","article-title":"PHOENIX 2 Investigators. Long-term efficacy and safety of ustekinumab, with and without dosing adjustment, in patients with moderate-to-severe psoriasis: results from the PHOENIX 2 study through 5 years of follow-up","volume":"172","author":"Langley","year":"2015","journal-title":"Br J Dermatol"},{"issue":"7","key":"10.1016\/j.idc.2020.02.001_bib65","first-page":"706","article-title":"Safety surveillance for ustekinumab and other psoriasis treatments fthe psoriasis longitudinal assessment and registry (PSOLAR)","volume":"14","author":"Papp","year":"2015","journal-title":"J\u00a0Drugs Dermatol"},{"issue":"6","key":"10.1016\/j.idc.2020.02.001_bib66","first-page":"1237","article-title":"Safety profile of biologic drugs in the therapy of Crohn disease: a systematic review and network metaanalysis","volume":"68","author":"Mocko","year":"2016","journal-title":"Pharmacol Rep"},{"key":"10.1016\/j.idc.2020.02.001_bib67","first-page":"293","article-title":"Next generation of biologics for the treatment of Crohn\u2019s disease: an evidence based- review on ustekinumab","volume":"10","author":"Jauregui-Amezaga","year":"2017","journal-title":"Clin Exp Gastroenterol"},{"key":"10.1016\/j.idc.2020.02.001_bib68","first-page":"1","article-title":"Tildrakizumab in the treatment of psoriasis: Latest evidence and place in therapy","volume":"10","author":"Pithadia","year":"2019","journal-title":"Ther Adv Chronic Dis"},{"key":"10.1016\/j.idc.2020.02.001_bib69","first-page":"1","article-title":"Nonclinical safety of tildrakizumab, a humanized anti\u2013IL-23p19 monoclonal antibody, in nonhuman primates","volume":"108","author":"Santostefano","year":"2019","journal-title":"Regul Toxicol Pharmacol"},{"key":"10.1016\/j.idc.2020.02.001_bib70","first-page":"276","article-title":"Tildrakizumab versus placebo or etanercept for chronic plaque psoriasis (reSURFACE 1 and reSURFACE 2): results from two randomised controlled, phase 3 trials","volume":"390","author":"Reich","year":"2017","journal-title":"Lancet"},{"key":"10.1016\/j.idc.2020.02.001_bib71","first-page":"212594","article-title":"Guselkumab for the treatment of psoriasis\u2013evidence to date","volume":"8","author":"Nogueira","year":"2019","journal-title":"Drugs Context"},{"key":"10.1016\/j.idc.2020.02.001_bib72","first-page":"1993","article-title":"Evaluating guselkimab: an anti-IL-23 antibody for the treatment of plaque psoriasis","volume":"13","author":"Yang","year":"2019","journal-title":"Drug Des Devel Ther"},{"issue":"3","key":"10.1016\/j.idc.2020.02.001_bib73","first-page":"689","article-title":"Safety and efficacy of guselkumab in Japanese patients with moderate-to-severe plaque psoriasis: a randomized, placebo-controlled, ascending-dosestudy","volume":"178","author":"Nemoto","year":"2018","journal-title":"Br J Dermatol"},{"issue":"3","key":"10.1016\/j.idc.2020.02.001_bib74","first-page":"405","volume":"76","author":"Blauvelt","year":"2017","journal-title":"J\u00a0Am Acad Dermatol"},{"issue":"3","key":"10.1016\/j.idc.2020.02.001_bib75","first-page":"418","volume":"76","author":"Reich","year":"2017","journal-title":"J\u00a0Am Acad Dermatol"},{"issue":"1","key":"10.1016\/j.idc.2020.02.001_bib76","first-page":"114","article-title":"Efficacy and safety of guselkumab in patients with psoriasis who have an inadequate response to ustekinumab: results of the randomized, double-blind, phase III NAVIGATE trial","volume":"178","author":"Langley","year":"2018","journal-title":"Br J Dermatol"},{"issue":"5","key":"10.1016\/j.idc.2020.02.001_bib77","first-page":"529","article-title":"Guselkumab, a human interleukin-23 monoclonal antibody in Japanese patients with generalized pustular psoriasis and erythrodermic psoriasis: efficacy and safety analyses of a 52-week, phase 3, multicenter, open-label study","volume":"45","author":"Sano","year":"2018","journal-title":"J\u00a0Dermatol"},{"issue":"3","key":"10.1016\/j.idc.2020.02.001_bib78","first-page":"780","article-title":"IL-17-mediated immunity to the opportunistic fungal pathogen candida albicans","volume":"195","author":"Conti","year":"2015","journal-title":"J\u00a0Immunol"},{"issue":"4","key":"10.1016\/j.idc.2020.02.001_bib79","first-page":"AB234","article-title":"Long-term safety of risankizumab in patients with moderate to severe psoriasis: analysis of pooled clinical trial data","volume":"81","author":"Leonardi","year":"2019","journal-title":"J\u00a0Am Acad Dermatol"},{"issue":"4","key":"10.1016\/j.idc.2020.02.001_bib80","first-page":"AB234","article-title":"Risankizumab treatment is associated with low and consistent infection rates over time in patients with moderate to severe psoriasis: analysis of pooled clinical trial data","volume":"81","author":"Strober","year":"2019","journal-title":"J\u00a0Am Acad Dermatol"},{"issue":"10198","key":"10.1016\/j.idc.2020.02.001_bib81","first-page":"576","article-title":"Risankizumab compared with adalimumab in patients with moderate-to-severe plaque psoriasis (IMMvent): a randomised, double-blind, active-comparator-controlled phase 3 trial","volume":"394","author":"Reich","year":"2019","journal-title":"Lancet"}],"container-title":["Infectious Disease Clinics of North America"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0891552020300039?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0891552020300039?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,11]],"date-time":"2025-10-11T15:14:19Z","timestamp":1760195659000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0891552020300039"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,6]]},"references-count":81,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2020,6]]}},"alternative-id":["S0891552020300039"],"URL":"https:\/\/doi.org\/10.1016\/j.idc.2020.02.001","relation":{},"ISSN":["0891-5520"],"issn-type":[{"type":"print","value":"0891-5520"}],"subject":[],"published":{"date-parts":[[2020,6]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Risk of Serious Infection Associated with Agents that Target T-Cell Activation and Interleukin-17 and Interleukin-23 Cytokines","name":"articletitle","label":"Article Title"},{"value":"Infectious Disease Clinics of North America","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.idc.2020.02.001","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2020 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}